Faure GC, Amsellem S, Arnoulet C, Bardet V, Campos L, De Carvalho-Bittencourt M, de Labarthe A, Eischen A, Feuillard J, Fossat C, Ottou FG, Guérin E, Guy J, Jouault H, Kuhlein E, Lacombe F, Lainey E, Maynadié M, Noguera ME, Roussel M, Solly F, Ballon OW, Béné MC. Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.
Immunol Lett 2010;
134:145-9. [PMID:
20951742 DOI:
10.1016/j.imlet.2010.10.008]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Revised: 10/07/2010] [Accepted: 10/07/2010] [Indexed: 11/26/2022]
Abstract
The B-cell panel of the ninth HLDA was applied in a multicentre fashion to cryopreserved cells from 46 patients with acute lymphoblastic leukemia. The reagents were aliquoted and shipped to volunteer participants from the French Groupe d'Etude Immunologique des Leucémies (GEIL). All samples were tested in flow cytometry, and the results collected as of the strength of labeling of the leukemic clone as negative, weak or strong. Among the 64 antibodies tested, the strongest and most frequent staining was observed for CD305 (LAIR), CD229 (Ly9), CD200 (OX-2) and, to a lesser extent, CD361 (EVI2b). Details of the observations, and information about the molecules tested are provided in the manuscript as well as a summary table.
Collapse